Clinical trials: Pancreatic Disorders
Advanced Solid Tumors, Pancreatic Cancer
Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
This study is an open label, two-part, First in Human (FIH) Phase 1/2 dose-finding study designed to determine the safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and proof-of-concept (POC) of OMO-103 in…
- Conditions
- Advanced Solid Tumors, Pancreatic Cancer, CRC
- Trial name
- MYCure (NCT04808362)
- Testing
- OMO-103
- Where
- 3 sites in Spain
- Volunteers
- 22 people
- Sponsor
- Peptomyc S.L.
Gastrointestinal Cancers, Cholangiocarcinoma
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma…
- Conditions
- Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer
- Trial name
- 18F-FAPI-74 GI (NCT05641896)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- SOFIE
Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2
A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2
maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in diabetes type II
- Trial name
- NCT02009410
- Testing
- Creon
- Where
- 10 sites in Germany, Spain
- Sponsor
- Abbott
Pancreatic Cancer, Advanced or Metastatic
Nimotuzumab in Adults With Pancreatic Cancer
CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER
- Trial name
- NCT00561990
- Testing
- Nimotuzumab
- Where
- Germany
- Volunteers
- 188 people
- Sponsor
- Oncoscience AG
Pancreatic Cancer
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
The purpose of this study is to see if LOAd703 (an oncolytic adenovirus) can be safely given to patients with pancreatic cancer.
- Trial name
- NCT02705196
- Testing
- delolimogene mupadenorepvec, gemcitabine, nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Lokon Pharma AB
Pancreatic Tumor, Benign, Pancreatic Neoplasms
Laser Tissue Welding - Distal Pancreatectomy Sealing Study
The laser tissue welding device is intended for use in patients requiring sealing of the pancreas after partial pancreatectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.
- Conditions
- Pancreatic Tumor, Benign, Pancreatic Neoplasms, Pancreatic Adenocarcinoma, Pancreatic Pseudocyst
- Trial name
- LTW (NCT03147768)
- Testing
- Distal Pancreatectomy Sealing Using LTW
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Laser Tissue Welding, Inc.
Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT06673017
- Testing
- PTM-101
- Where
- 9 sites in United States, Australia
- Volunteers
- 26 people
- Sponsor
- PanTher Therapeutics
Pancreatic Neoplasms
Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer
This study is being conducted to evaluate the clinical efficacy, biologic activity (inhibition of PX-12 target thioredoxin-1) and effects of an expired metabolite of PX-12 in patients with advanced pancreatic cancer.
- Trial name
- NCT00417287
- Testing
- PX-12
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cascadian Therapeutics Inc.
Neoplasms Pancreatic
Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer
Thermotherapy is a technology aiming at destroying tissue, for example tumor tissue. Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue…
- Trial name
- NCT02973217
- Testing
- Immunostimulating Interstitial Laser Thermotherapy
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Clinical Laserthermia Systems AB
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
- Conditions
- Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma
- Trial name
- RAD301 (NCT05799274)
- Testing
- RAD301 ([68Ga]-RAD301)
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Radiopharm Theranostics, Ltd
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Cystic Fibrosis
A Multi-Center Study of the CF Quantum® Sweat Test System
This is an observational comparative study to compare the standard-of-care methods for sweat testing used to support diagnosing cystic fibrosis (CF) against a new method of sweat testing called the CF Quantum Sweat Test System.
- Trial name
- NCT02404714
- Testing
- Iontophoresis sweat test
- Where
- 6 sites in United States
- Volunteers
- 55 people
- Sponsor
- Polychrome Medical, Inc.
Advanced Unresectable Pancreatic Cancer
GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer
To investigate the efficacy of GV1001 in sequential combination with gemcitabine in locally advanced and metastatic adenocarcinoma of the pancreas.
- Trial name
- NCT00358566
- Testing
- GV1001, Gemcitabine (Chemotherapy)
- Where
- 86 sites in United States, Australia and 10 more
- Volunteers
- 360 people
- Sponsor
- Pharmexa A/S
Breast Cancer, Colorectal Cancer
Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- CDX1307-02 (NCT00648102)
- Testing
- CDX-1307
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Cachexia, Pancreatic Neoplasms
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia
The purpose of this study is to evaluate the effectiveness and safety of infliximab, the active ingredient in Remicade, for the treatment of cachexia in pancreatic cancer patients who are receiving chemotherapy with gemcitabine.
- Trial name
- NCT00060502
- Testing
- Infliximab; Gemcitabine
- Volunteers
- 73 people
- Sponsor
- Centocor, Inc.
Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize (Mucin 1) MUC1 is safe and effective for patients with relapsed or refractory solid tumor.
- Conditions
- Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Pancreatic Carcinoma, Triple-Negative Invasive Breast Carcinoma
- Trial name
- NCT02587689
- Testing
- anti-MUC1 CAR T Cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Pancreatic Cancer, Proton Therapy
Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer
This is an interventional, single arm, open-label, feasibility trial with gemcitabine and nab-paclitaxel, followed by concomitant proton therapy and capecitabine, followed by re-evaluation and surgery (when feasible) for patients…
- Trial name
- PARC (NCT04894643)
- Testing
- Proton Ions, Nab-PACLitaxel, Gemcitabine
- Where
- 2 sites in Austria
- Volunteers
- 10 people
- Sponsor
- EBG MedAustron GmbH
Ovarian Neoplasms, Breast Neoplasms
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP).
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
- Trial name
- FiREBOLT (NCT07213791)
- Testing
- LY4337713
- Where
- 30 sites in United States, China and 3 more
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer
The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.
- Trial name
- NCT00055250
- Testing
- Gemcitabine, LY293111
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Trial name
- NCT06974734
- Testing
- PF-08046037, sasanlimab
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.